Business
Oncolytics Biotech(R) Presents Clinical Data Highlighting the Effectiveness of Intravenous Delivery to and Replication of Pelareorep in Tumors
Across 13 clinical studies and a broad range of cancers, up to 96 percent of tumor samples t...
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"\nOncolytics Biotech(R) Presents Clinical Data Highlighting the Effectiveness of Intravenous Delivery to and Replication of Pelareorep in TumorsAcross 13 clinical studies and a broad range of cancers, up to 96 percent of tumor samples tested positive for replicating pelareorep virus after intravenous deliveryPelareorep is the only oncolytic virus with meaningful clinical data demonstrating intravenous delivery to tumor tissueSAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / October 15, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that the results of a metanalysis of 13 clinical studies of the Company's systemically delivered oncolytic reovirus, pelareorep, were presented during a podium presentation at the annual International Oncolytic Virus Conference (IOVC), hosted at the Mayo Clinic in Rochester, MN on October 9-12, 2019. The analyses examined the effectiveness of viral replication within the tumors of patients treated systemically with pelareorep. The data demonstrated that, unlike other oncolytic viruses that require intra-tumoral delivery, intravenous (IV) systemic delivery of pelareorep resulted in 81% of patient tumor samples across multiple types of cancer testing positive for virus replication, with no infection in normal tissue. These results are from studies across a broad range of solid and liquid tumors, including metastatic disease.\"This metanalysis across multiple clinical studies provides definitive proof that pelareorep can effectively be delivered intravenously, further demonstrating pelareorep's ability to avoid neutralization, reach primary and metastatic disease and be a valuable therapy and immune adjuvant across a wide range of cancers,\" said Dr. Matt Coffey, President and CEO of Oncolytics Biotech. \"By effectively and selectively targeting and replicating within tumor cells, systemically delivered pelareorep causes inflammation, labelling the tumor microenvironment with viral RNA priming the patient's immune system. Combined with PD-1/PD-L1 checkpoint inhibition to enhance the anti-tumor immune response, pelareorep is uniquely positioned to become a backbone for many leading immuno-oncology combination regimens.\"Key Findings from the MetanalysisAfter IV delivery, 81% of patient tumor sampl...